Reviewer #1:

Scientific Quality: Grade D (Fair)

Language Quality: Grade B (Minor language polishing)

Conclusion: Major revision

Specific Comments to Authors: Generally, this study is a bit superficial and descriptive. Some specific comments are listed.

1. The beginning of a sentence should not start with an Arabic numeral. For example, the authors said “149 patients (74%) reported with ...” in the 19th line of page 3.

Revised

2. In the 8th line of page 5, “(UGIB” should be revised as “(UGIB)”.

Revised

3. In the 7th line of page 6, check formatting errors.

Revised

4. In the 17th line of page 6, the authors mentioned querying the database from January 2013 to August 2023, but previously mentioned querying the database from June 2013 to August 2023.

This was a typographical error and has been corrected.

5. In the 11th line of page 7, the full name of “ERCP” was not written when it first appeared.

Revised

6. In the Table 1a and 1b, the full names of “EGD” and “ERCP” were not written when they first appeared.

Revised

7. The discussion on IGP reports exceeding GP reports is not enough, and the reasons should be discussed and analyzed.

Unfortunately, the MAUDE database does not allow us to specifically the reasons that were associated with the events thus making it difficult to analyze why IGP had more events than GP.

8. Discuss and analyze why the number of GP and IGP devices reports has decreased after 2017. Discuss and analyze the connection between device issues and patient complications in the event.

This has been included.

Reviewer #2:

Scientific Quality: Grade C (Good)

Language Quality: Grade A (Priority publishing)

Conclusion: Minor revision

Specific Comments to Authors: This search elicited 140 reports for Gold Probe and 202 reports for Injection Gold Probe during the study period from January 2013 to August 2023. The results showed that malfunctions reportedly occurred in 130 cases for GP, and actual patient injury or event occurred in 10 patients. 149 patients (74%) reported with Injection Gold Probe events suffered no significant consequences due to the device failure, but 53 patients (26%) were affected by an event. This study of the FDA MAUDE database revealed the type, number, and trends of reported device-related adverse events. The endoscopist and support staff must be aware of these

device-related events and be equipped to manage them if they occur. I think the work is interesting and can be accepted for publication in the journal. As a reader, I also want to find some proceedings summary on the recent progress of endoscopic hemostasis (like hydrogel, power, etc: https://doi.org/10.1016/j.ijbiomac.2023.125754), which should be emphasized during the revision.

A paragraph has been added to the manuscript.